Adding Megestrol to Letrozole Enhances Antiproliferative Effects in ER+ Breast Cancer: Insights from the PIONEER Trial

Adding Megestrol to Letrozole Enhances Antiproliferative Effects in ER+ Breast Cancer: Insights from the PIONEER Trial

The Phase 2b PIONEER trial reveals that adding megestrol to letrozole significantly reduces tumor proliferation in early-stage ER+ breast cancer. By reprogramming estrogen receptor activity, this combination offers a dual benefit of enhanced antitumor efficacy and potential improvement in treatment adherence through hot flash mitigation.
More Is Not Always Better: Long-term Data from the SAKK 09/10 Trial Refutes Dose-intensified Salvage Radiotherapy for Prostate Cancer

More Is Not Always Better: Long-term Data from the SAKK 09/10 Trial Refutes Dose-intensified Salvage Radiotherapy for Prostate Cancer

Long-term results from the SAKK 09/10 trial demonstrate that dose-intensified salvage radiotherapy (70 Gy) provides no oncological benefit over conventional dosing (64 Gy) in patients with biochemical recurrence after prostatectomy, while significantly increasing the risk of long-term gastrointestinal toxicity.
Optimizing Immunotherapy in Triple-Negative Breast Cancer: Reduced-Dose Folate Receptor Alpha Vaccine Shows Robust Efficacy Without Cyclophosphamide Pretreatment

Optimizing Immunotherapy in Triple-Negative Breast Cancer: Reduced-Dose Folate Receptor Alpha Vaccine Shows Robust Efficacy Without Cyclophosphamide Pretreatment

A Phase II trial demonstrates that a reduced-dose Folate Receptor Alpha (FRα) vaccine is safe and highly immunogenic in triple-negative breast cancer patients, achieving robust T-cell responses comparable to high-dose regimens and eliminating the need for cyclophosphamide pretreatment.
Music Therapy Proves Noninferior to Cognitive Behavioral Therapy for Managing Anxiety in Cancer Survivors: Results from a Randomized Trial

Music Therapy Proves Noninferior to Cognitive Behavioral Therapy for Managing Anxiety in Cancer Survivors: Results from a Randomized Trial

A randomized clinical trial demonstrates that telehealth-delivered music therapy is noninferior to cognitive behavioral therapy for reducing anxiety in cancer survivors, providing durable, clinically meaningful improvements and a viable alternative to traditional psychological interventions.
Triple-Drug Regimen with Tiragolumab and Atezolizumab Shows Superior Response in First-Line Esophageal Cancer: The MORPHEUS-EC Trial

Triple-Drug Regimen with Tiragolumab and Atezolizumab Shows Superior Response in First-Line Esophageal Cancer: The MORPHEUS-EC Trial

The phase 1b/2 MORPHEUS-EC trial demonstrates that adding the anti-TIGIT antibody tiragolumab to atezolizumab and chemotherapy significantly improves objective response rates (67.7%) in patients with previously untreated, locally advanced or metastatic esophageal cancer, providing a promising new therapeutic strategy.